U.S. Life Sciences Stock News

In February 2026, The Timken Company announced a new share repurchase authorization of up to 10,000,000 shares through February 28, 2031, reaffirmed its quarterly dividend at US$0.35 per share, and outlined ongoing plans for mergers and acquisitions alongside changes to its board leadership. These moves collectively highlight Timken’s emphasis on capital return, portfolio expansion in areas like humanoid robotics, and governance continuity during an audit committee transition. We’ll now...

The Hartford’s board recently declared a US$0.60 per-share common dividend payable on April 2 and a US$375 Series G preferred dividend payable on May 15, reinforcing its ongoing role in property and casualty insurance, employee benefits, and mutual funds. Amid analyst forecasts for softer near-term revenue, the combination of fresh dividends and faster book-value growth highlights management’s emphasis on capital return backed by strengthening assets. Next, we’ll explore how this new...

Why Garrett Motion’s MEG Turbocharger Launch With Weichai Matters Garrett Motion (GTX) has put its new MEG turbocharger platform into first commercial use with Weichai’s next generation large bore engines, targeting marine propulsion and power generation markets. This first deployment takes Garrett’s turbo technology into larger frame applications that are engineered for demanding operating conditions, including marine vessels, high output power plants, and backup gensets for critical...

Coca-Cola Consolidated (COKE) has just reported fourth quarter and full year 2025 results, with sales and profit moving in different directions. This gives investors fresh numbers to reassess the stock after a strong year of returns. See our latest analysis for Coca-Cola Consolidated. The fresh results come after a strong run in the share price, with a 30 day share price return of 12.42% and a 1 year total shareholder return of 21.73% off a US$170.29 share price. Over the longer term,...

On January 20, Japan’s Ministry of Health, Labour and Welfare granted Orphan Drug designation to Dyne Therapeutics’ investigational DM1 treatment zeleciment-basivarsen, which has shown early and sustained improvements in myotonia, muscle strength and function alongside a favorable safety profile. This additional Orphan Drug status, on top of designations already secured in the U.S. and Europe, underscores global regulatory recognition of the urgent unmet need in myotonic muscular dystrophy...

Halozyme Therapeutics (HALO) closed out FY 2025 with fourth quarter revenue of US$451.8 million and a basic EPS loss of US$1.20, compared with Q4 2024 revenue of US$298.0 million and basic EPS of US$1.08. Over the past year, the company has seen quarterly revenue move from US$290.1 million in Q3 2024 to US$354.3 million in Q3 2025, while basic EPS shifted from US$1.08 to US$1.49 over the same quarters, creating a mixed picture for margins as investors digest the latest numbers. See our full...

Why Dollar Tree’s upgrade is back in focus Rothschild & Co Redburn’s recent upgrade of Dollar Tree (DLTR) put fresh attention on the retailer’s multi price rollout and earnings outlook, even as the company manages customer backlash and cost pressures. See our latest analysis for Dollar Tree. Dollar Tree’s share price has been volatile, with a 34.48% 90 day share price return and a 5.29% 1 month share price decline, while the 1 year total shareholder return sits at 75.27%, suggesting momentum...

Glaukos (GKOS) has just posted its FY 2025 numbers with Q4 revenue of US$143.1 million and a basic EPS loss of US$2.32, alongside a trailing twelve month revenue line of US$507.4 million and a basic EPS loss of US$3.28. Over recent quarters, the company has seen revenue move from US$96.7 million in Q3 2024 to US$105.5 million in Q4 2024 and then to US$143.1 million in Q4 2025, while quarterly basic EPS losses shifted from US$0.39 in Q3 2024 to US$0.60 in Q4 2024 and US$2.32 in Q4 2025. For...

If you are wondering whether Ciena's share price still lines up with its underlying value, you are not alone. This article will walk through what the current market price might be implying. Ciena closed at US$310.96, with returns of 4.6% over the last 7 days, 27.7% over 30 days, 26.4% year to date, 257.2% over 1 year and a very large gain over 3 and 5 years. Recent headlines around Ciena have kept attention on the stock, as investors weigh what the current price means for long term...

If you are wondering whether Macy's current share price still offers value, this article will walk through what the numbers are saying and how that might fit with your own view of the business. Macy's shares last closed at US$22.77, with returns of 4.8% over the past 7 days, 4.7% over 30 days, 0.1% year to date, 55.7% over 1 year, 24.4% over 3 years, and 77.0% over 5 years. Recent headlines around Macy's have focused on the company as a department store brand in a changing retail market and...

If you are wondering whether Oshkosh is still reasonably priced after its recent run, this article will walk through what the current share price might be implying about value. Oshkosh shares last closed at US$171.58, with returns of 12.7% over the past 30 days, 29.8% year to date, 58.9% over 1 year, 101.2% over 3 years, and 64.7% over 5 years. Many investors are asking what is already priced in. Recent headlines have focused on Oshkosh in the context of ongoing interest in capital goods and...

Grand Canyon Education (LOPE) has just released its full year 2025 results and issued detailed 2026 guidance, providing fresh numbers on earnings, margins and service revenue targets for each quarter. See our latest analysis for Grand Canyon Education. The shares have reacted positively to the new 2025 results and 2026 guidance, with a 1-day share price return of 3.35% and a 7-day return of 4.68%, although the 30-day return of a 5.89% decline tempers that short term momentum. Over a longer...

In the first quarter ended December 31, 2025, CleanSpark, Inc. reported a net loss of US$378.71 million, reversing from net income of US$246.79 million a year earlier as earnings per share swung from profit to loss. This sharp shift in profitability has prompted analysts to reassess the company’s outlook in light of lower bitcoin prices and operational uncertainty. Against this backdrop, we’ll examine how the earnings swing and related analyst caution may reshape CleanSpark’s broader...

Snowflake (NYSE:SNOW) has introduced Cortex Code, a coding agent designed to help developers build on its data cloud using AI. The company has entered high profile partnerships with OpenAI and Anthropic to integrate advanced models into its platform. Snowflake is expanding real world AI use cases, including deployments with Wolfspeed in manufacturing and U.S. Figure Skating in sports analytics. Snowflake sits at the intersection of cloud data infrastructure and applied AI, which places...

AtriCure (ATRC) just posted its FY 2025 numbers with Q4 revenue of US$140.5 million and basic EPS of US$0.04 on net income of US$1.8 million, while on a trailing twelve month basis the company remains loss making with basic EPS at US$0.24 and net income of US$11.4 million. The company has seen quarterly revenue move from US$124.3 million in Q4 2024 to US$140.5 million in Q4 2025. Over the same periods, basic EPS shifted from a loss of US$0.33 to a small profit of US$0.04. This sets up a story...

In the past week, attention has intensified on SoundHound AI ahead of its now-passed Q4 2025 earnings release, as investors weighed heavy short interest, expectations for faster revenue growth, and the impact of a billion-dollar contract backlog that has begun converting into sales. At the same time, expanding commercial deployments, from restaurant ordering partnerships with Five Guys to enterprise solutions via Bridgepointe Technologies, are testing whether SoundHound’s voice AI can...

If you are wondering whether CME Group at around US$302 per share is priced for perfection or still offers value, this article walks you through what the current market price might be implying. The stock has been flat over the last 7 days, but is up 8.2% over 30 days, 12.2% year to date, 23.0% over 1 year, 80.9% over 3 years and 82.2% over 5 years. This raises fair questions about what is already reflected in the price. Recent coverage around CME Group has focused on its role as a major...

LPL Financial Holdings (LPLA) just announced a new agreement with Simplicity Group, which will become LPL’s preferred Brokerage General Agency and take over its internal insurance business starting May 1, 2026. See our latest analysis for LPL Financial Holdings. The Simplicity agreement lands at a time when LPL Financial Holdings’ share price, at US$332.18, has had a 12.3% decline over 30 days and an 8.1% decline year to date, while the 5 year total shareholder return of 151.6% reflects much...

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported long term phase II extension data for duvakitug in ulcerative colitis and Crohn’s disease. The RELIEVE UCCD extension study showed durable clinical and endoscopic efficacy over 44 weeks with a favorable safety profile. The partners plan to move duvakitug rapidly into phase III trials as a potential TL1A antibody option in inflammatory bowel disease. For Teva, with a current share price of $34.11, this is a meaningful pipeline...

CNX Resources (CNX) is in focus after announcing a US$500 million issue of 5.875% senior notes due 2034, with proceeds earmarked to retire existing 6.000% notes maturing in 2029. See our latest analysis for CNX Resources. The refinancing news comes at a time when CNX Resources' share price has gained 11.45% over the past 30 days and 9.36% over 90 days. Its 1 year total shareholder return of 32.76% and very large 3 and 5 year total shareholder returns suggest longer term momentum that...

Entegris (ENTG) is back in focus after fourth quarter results topped analyst forecasts. Management pointed to strength in advanced node semiconductor applications and solid demand for CMP consumables and liquid filtration products. See our latest analysis for Entegris. At a share price of US$131.89, Entegris has logged a 91.7% 90 day share price return and a 47.26% year to date share price return. The 1 year total shareholder return of 22.65% points to momentum that has recently...

If you are wondering whether Chipotle Mexican Grill’s current share price still makes sense after a strong multi year run, this article will walk through what that price actually implies about the company’s value. The stock last closed at US$38.72, with a 4.0% return over the past 7 days, a 3.3% return year to date, a 28.0% decline over the last year, and longer term returns of 24.7% over 3 years and 33.6% over 5 years. Recent news coverage has focused on Chipotle’s store expansion plans,...

Why Host Hotels & Resorts Is Back on Investors’ Radar Host Hotels & Resorts (HST) has drawn fresh attention after a solid stretch of share gains, including around 9% over the past month and about 21% in the past 3 months. Those moves come alongside annual revenue of roughly US$5.95b and net income of about US$738m, prompting investors to reassess what they are paying today for one of the largest lodging REITs in the S&P 500. See our latest analysis for Host Hotels & Resorts. Beyond the recent...

NextEra Energy (NYSE:NEE) has received approval for a 220 mile high voltage transmission project developed with Exelon, expanding its role in regional grid infrastructure. The company is pairing this grid buildout with renewable projects and power arrangements that support large data center operators. Recent partnerships with major technology firms, including Meta and Google, tie new clean energy capacity to rising computing and AI power needs. For investors watching NYSE:NEE, this...